Skip to main content

Table 6 Comparison of the areas under ROC for NLR and other biomarkers to predict future exacerbations and low % FEV1 (% FEV1 < 50%)

From: Clinical utility of blood neutrophil-lymphocyte ratio in Japanese COPD patients

Exacerbation AUC (95% CI)
 NLR 63.4 (55.0–71.7)
 Neutrophil count 55.2 (46.3–64.2)
 Lymphocyte count 59.2 (50.8–67.6)
 Eosinophil count 51.2 (41.9–60.6)
 CRP 54.3 (45.2–63.4)
 SAA 59.4 (50.5–68.3)
% FEV1 < 50% AUC (95% CI)
 NLR 64.2 (56.9–71.6)
 Neutrophil count 55.3 (47.3–63.2)
 lymphocyte count 59.8 (52.3–67.3)
 Eosinophil count 51.5 (43.4–59.6)
 CRP 55.5 (47.7–63.5)
 SAA 57.7 (49.8–65.6)
  1. NLR Neutrophil-to-Lymphocyte ratio, CRP C-reactive protein, SAA serum amyloid A